EP1181287A1 - Sulfonamide compounds with pharmaceutical activity - Google Patents

Sulfonamide compounds with pharmaceutical activity

Info

Publication number
EP1181287A1
EP1181287A1 EP00935141A EP00935141A EP1181287A1 EP 1181287 A1 EP1181287 A1 EP 1181287A1 EP 00935141 A EP00935141 A EP 00935141A EP 00935141 A EP00935141 A EP 00935141A EP 1181287 A1 EP1181287 A1 EP 1181287A1
Authority
EP
European Patent Office
Prior art keywords
toluene
sulfonyl
piperidin
ylmethyl
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00935141A
Other languages
German (de)
French (fr)
Inventor
Peter John SmithKline Beecham Pharm. LOVELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1181287A1 publication Critical patent/EP1181287A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
  • WO 97/29097, WO 97/48681 and WO 97/49695 all disclose a series of sulphonamide derivatives that are 5-HT ⁇ receptor antagonists and are said to be useful in the treatment of various CNS diseases.
  • a structurally novel class of compounds have now been found that also possess 5-HT7 receptor activity.
  • the present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • R.1, R2 and R ⁇ are independently hydrogen, halogen, hydroxy, C galkyl or C ⁇ . galkoxy; m is 1 or 2,
  • X is nitrogen, carbon or CH, is a single bond when X is nitrogen or a CH; or is a double bond when X is carbon;
  • P is phenyl, naphthyl, a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
  • R 4 is C ⁇ _6alkyl optionally substituted by NR 5 R 6 , aryl, arylC ⁇ .g alkyl, Cj.galkoxy, C ⁇ 6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR 5 R 6 , CONR 5 R 6 ,
  • Ci .galkyl groups whether alone or as part of another group may be straight chain or branched.
  • the term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
  • the term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl or naphthyl. Such aryl groups may be optionally substituted by one or more C ⁇ _ galkyl or halogen.
  • the groups R , R ⁇ and R ⁇ are independently hydrogen, halogen such as fluorine, chlorine or bromine or C ⁇ _ galkyl such as methyl.
  • D is a single bond.
  • P is naphthyl this is intended to denote both naphthalen-1-yl and naphthalen-2-yl groups.
  • P is a 5 or 6 membered heteroaryl ring
  • suitable examples include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl.
  • P is a benzofused heteroaryl ring suitable examples include indolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl and isoquinolinyl.
  • P is phenyl, naphthyl, benzimidazol-2-yl, 2-oxo-2,3 -dihydrobenzimidazol-1-yl, indol-3-yl, benzoxazol-2-yl and benzothiazol-2- yi-
  • R 4 groups include halogen such as fluorine or chlorine, Ci .galkyl optionally substituted by NR ⁇ R6 such as methyl, hydroxy, CF3, C ⁇ _ galkoxy such as methoxy or groups COR 7 or CO2R 7 in which R 7 is methyl.
  • n 2 or more the groups R 4 can be the same or different.
  • n is 0 or 1.
  • Particularly preferred compounds of the invention include: (R)-2-( 1 -( 1 -(Toluene-3-sulfony l)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzimidazole, (S)-2-( 1 -( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-y 1)- 1 H- benzimidazole,
  • the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
  • the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
  • the invention also extends to any tautomeric forms and mixtures thereof.
  • the present invention also provides, in a further aspect, a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises coupling a compound of formula (II):
  • Suitable leaving groups Y include halogen (particularly chloro) and OSO2Nr groups such as tosylate.
  • the reaction of a compounds of formulae (II) and (III) is preferably carried out in a solvent such as dichloromethane or acetonitrile optionally in the presence of sodium iodide and a base such as potassium carbonate.
  • Compounds of formula (I) and their pharmaceutically acceptable salts have 5-HT7 receptor antagonist activity and are believed to be of potential use for the treatment or prophylaxis of certain CNS disorders such as anxiety, depression, sleep disorders (including disturbances of Circadian rhythms), migraine, Parkinson's disease, schizophrenia, pain, appetite disorders and other indications such as inflammation, spastic colon, renal disorders, hypotension, cardiovascular shock, disorders associated with neuronal degeneration resulting from ischaemic events such as stroke, septic shock and gastrointestinal diseases such as IBS (irritable bowel syndrome).
  • CNS disorders such as anxiety, depression, sleep disorders (including disturbances of Circadian rhythms), migraine, Parkinson's disease, schizophrenia, pain, appetite disorders and other indications such as inflammation, spastic colon, renal disorders, hypotension, cardiovascular shock, disorders associated with neuronal degeneration resulting from ischaemic events such as stroke, septic shock and gastrointestinal diseases such as IBS (irritable bowel syndrome).
  • IBS irritable bowel syndrome
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders, particularly depression and/or sleep disorders.
  • the invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof for use in the treatment or prophylaxis of depression and/or sleep disorders.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.
  • the title compound can be prepared according to procedures described in J. Med.
  • the title compound can be prepared according to procedures described in J. Med. Chem., 1992, 35(26), 4813.
  • Examples El 3 - El 8 shown in Table 2 were prepared using the procedure described in Example 1 using D3 and a 4-substituted piperidine or piperazine. Such reagents are either commercially available or can be prepared by methods described above.
  • the affinity of the compounds of this invention for the 5-HT7 receptor binding site can be determined by methods described in WO 97/29097.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The invention relates to novel sulphonamide compounds having 5-HT7 antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

Description

SULFONAMIDE COMPOUNDS WITH PHARMACEUTICAL ACTIVITY
This invention relates to compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
WO 97/29097, WO 97/48681 and WO 97/49695 all disclose a series of sulphonamide derivatives that are 5-HTγ receptor antagonists and are said to be useful in the treatment of various CNS diseases.
A structurally novel class of compounds have now been found that also possess 5-HT7 receptor activity. The present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:
(I) wherein:
R.1, R2 and Rø are independently hydrogen, halogen, hydroxy, C galkyl or C\. galkoxy; m is 1 or 2,
X is nitrogen, carbon or CH, is a single bond when X is nitrogen or a CH; or is a double bond when X is carbon;
D is a single bond, C=O, O or CH2 subject to the proviso that when X is nitrogen then D is not oxygen;
P is phenyl, naphthyl, a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
R4 is Cι_6alkyl optionally substituted by NR5R6, aryl, arylC^.g alkyl, Cj.galkoxy, Cμ6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR5R6, CONR5R6,
NR5COR6, S(O)pNR5R6, CHO, OCF3, SCF3, COR?, CH2OR7, CO R7 or OR7 where p is 0. 1 or 2 and R^, R and R are independently hydrogen, Cj .galkyl, aryl or arylCj .galkyl; n is 0, 1, 2 or 3.
Ci .galkyl groups whether alone or as part of another group may be straight chain or branched. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine. The term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl or naphthyl. Such aryl groups may be optionally substituted by one or more C\_ galkyl or halogen. Suitably the groups R , R^ and R^ are independently hydrogen, halogen such as fluorine, chlorine or bromine or C\_ galkyl such as methyl. Preferably the group R! is a methyl group with a meta relationship with respect to the sulphonamide linkage and both R^ and R^ are hydrogen. Preferably D is a single bond. When P is naphthyl this is intended to denote both naphthalen-1-yl and naphthalen-2-yl groups. When P is a 5 or 6 membered heteroaryl ring suitable examples include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl. When P is a benzofused heteroaryl ring suitable examples include indolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl and isoquinolinyl. The groups listed above can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom. It will be appreciated however, that when D is O then the heteroaryl or benzofused heteroaryl ring must be linked to the rest of the molecule via a carbon atom. Preferably P is phenyl, naphthyl, benzimidazol-2-yl, 2-oxo-2,3 -dihydrobenzimidazol-1-yl, indol-3-yl, benzoxazol-2-yl and benzothiazol-2- yi-
Preferred examples of R4 groups include halogen such as fluorine or chlorine, Ci .galkyl optionally substituted by NR^R6 such as methyl, hydroxy, CF3, Cι_ galkoxy such as methoxy or groups COR7 or CO2R7 in which R7 is methyl. When n is 2 or more the groups R4 can be the same or different. Preferably n is 0 or 1.
Particularly preferred compounds of the invention include: (R)-2-( 1 -( 1 -(Toluene-3-sulfony l)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzimidazole, (S)-2-( 1 -( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-y 1)- 1 H- benzimidazole,
(RS)-2-( 1 -( 1 -(Toluene-3 -sulfony l)-piperidin-2-ylmethyl)-piperidin-4-y 1)- 1 H- benzimidazole, (R)-5-Fluoro-2-( 1 -( 1 -(toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzimidazole,
(S)-5-Fluoro-2-(l-(l-(toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)-lH- benzimidazole, (RS)-5-Fluoro-2-(l-(l-(toluene-3-sulfonyl)-piperidin-2-ylmethyl)-piperidin-4-yl)-lH- benzimidazole,
(R)-2-( 1 -( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2-y lmethyl)-piperidin-4-y 1)- 1 H- benzoxazole,
(S)-2-( 1 -( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzoxazole,
(RS)-2-( 1 -( 1 -(Toluene-3-sulfonyl)-piperidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzoxazole,
(R)-2-(4-( 1 -(Toluene-3-sulfonyl)-pyrrolidin-2ylmethyl)-piperazin- 1 -yl)- 1 H- benzimidazole, (S)-2-(4-( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2ylmethyl)-piperazin- 1 -y 1)- 1 H- benzimidazole,
(RS)-2-(4-( 1 -(Toluene-3 -sulfonyl)-piperidin-2ylmethyl)-piperazin- 1 -y 1)- 1 H- benzimidazole,
(R)-l-(2-Methoxy-phenyl)-4-(l -(toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)- piperazine,
(S)-l-(2-Methoxy-phenyl)-4-(l-(toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)- piperazine,
(RS)- 1 -(2-Methoxy-phenyl)-4-( 1 -(toluene-3 -sulfonyl)-piperidin-2-ylmethyl)- piperazine, (R)-3-(l-(l-(Toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)-lH-indole,
(S)-3 -( 1 -( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-y 1)- 1 H-indole,
(RS)-3-( 1 -( 1 -(Toluene-3-sulfonyl)-piperidin-2-ylmethyl)-piperidin-4-yl)- 1 H-indole or a pharmaceutically acceptable salt thereof.
The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
Compounds of formula (I) may also form solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.
Certain compounds of formula (I) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.
The present invention also provides, in a further aspect, a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises coupling a compound of formula (II):
(II) in which R*, R^, R3 and m are as defined in formula (I) and Y is a leaving group with a compound of formula (III):
H
(III) in which , X, D, P, n and R4 are as defined in formula (I); and optionally thereafter if appropriate: • removing any protecting groups; • forming a pharmaceutically acceptable salt.
Suitable leaving groups Y include halogen (particularly chloro) and OSO2Nr groups such as tosylate. The reaction of a compounds of formulae (II) and (III) is preferably carried out in a solvent such as dichloromethane or acetonitrile optionally in the presence of sodium iodide and a base such as potassium carbonate.
Those skilled in the art will appreciate that it may be necessary to protect certain groups. Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981). Compounds of formulae (II) and (III) are described herein, are commercially available or may be prepared according to known methods or analogous to known methods. Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
Compounds of formula (I) and their pharmaceutically acceptable salts have 5-HT7 receptor antagonist activity and are believed to be of potential use for the treatment or prophylaxis of certain CNS disorders such as anxiety, depression, sleep disorders (including disturbances of Circadian rhythms), migraine, Parkinson's disease, schizophrenia, pain, appetite disorders and other indications such as inflammation, spastic colon, renal disorders, hypotension, cardiovascular shock, disorders associated with neuronal degeneration resulting from ischaemic events such as stroke, septic shock and gastrointestinal diseases such as IBS (irritable bowel syndrome).
Thus, the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders, particularly depression and/or sleep disorders.
The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In particular the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof for use in the treatment or prophylaxis of depression and/or sleep disorders. The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.
When administered in accordance with the invention, no unacceptable toxicological effects are expected with the compounds of the invention.
The following Descriptions and Examples illustrate the preparation of the compounds of the invention.
Description 1 (R)-Toluene-3-sulfonic acid l-(toluene-3-sulfonyl)-pyrrolidin-2-yl methyl ester (Dl)
Diisopropylethylamine (8.6 mL, 49 mmol) and toluene-3 -sulfonyl chloride (8.3 g, 44 mmol) were added to a solution of D-prolinol (2.0 g, 20mmol) in dichloromethane (100ml). The resulting solution was heated to reflux for 15 hours. Upon cooling, the solution was added to 100 mL of saturated aqueous sodium bicarbonate. The organic phase was separated, dried over sodium sulphate and concentrated in vacuo. The residue was purified by silica gel chromatography to afford the title compound (1.6g, 19%).
IH NMR (250MHz, CDC13) 7.75 (2H, m), 7.59 (2H, m), 7.48 (2H, m), 7.40 (2H, m), 4.26 (IH, dd, 9.9, 3.4Hz), 4.00 (IH, dd, 9.9, 7.9Hz), 3.77 (IH, m), 3.40 (IH, m), 3.08 (IH, m), 2.47 (3H, s), 2.43 (3H, s), 1.89 - 1.55 (4H, m). MS m/e 410 (MH+).
Description 2
(S)-Toluene-3-sulfonic acid l-(toluene-3-sulfonyl)-pyrrolidin-2-yI methyl ester (D2)
The title compound was prepared L-prolinol using the method described in Description 1. IH NMR (250MHz, CDCI3) 7.75 (2H, m), 7.59 (2H, m), 7.48 (2H, m), 7.40 (2H, m), 4.26 (IH, dd, 9.9, 3.4Hz), 4.00 (IH, dd, 9.9, 7.9Hz), 3.77 (IH, m), 3.40 (IH, m), 3.08 (IH, m), 2.47 (3H, s), 2.43 (3H, s), 1.89 - 1.55 (4H, m). MS m/e 410 (UK).
Description 3 (R5)-Toluene-3-sulfonic acid l-(toluene-3-sulfonyl)-piperidin-2-yl methyl ester (D3)
The title compound was prepared piperidine-2-methanol using the method described in Description 1.
IH NMR (CDCI3) 7.66 - 7.63 (4H, m), 7.46 (2H, m), 7.35 (2H, m), 4.26 (IH, m), 4.11 (2H, m), 3.72 (IH, brd, 13.7Hz), 2.83 (IH, m), 2.45 (3H, s), 2.42 (3H, s), 1.70 (IH, m), 1.60 - 1.31 (5H, m). MS m/e 424 (MH+).
Description 4 4-(Benzimidazol-2-yl)piperidine (D4) A mixture of 4-piperidine carboxylic acid (5.30g, 40mmol), 1 ,2-diaminobenzene (4.32g, 40mmol) and polyphosphoric acid (40g) were heated to 190°C for 14 hours, cooled, diluted with water (150ml) and basified with 50% KOH to pH 8. The solution was cooled in an ice/salt bath to give a precipitate which was collected by filtration and washed with water. The solid was dried in vacuo to afford the title compound (8.0g, 100%).
IH NMR (CDCI3) 7.48 (2H, m), 7.09 (2H, m), 3.04 (2H, m), 2.92 (2H, m), 2.60 (2H, m), 2.55 (IH, m), 1.95 (2H, m), 1.71 (2H, m). MS m/e 202 (MH+). Description 5 4-(5-fluorobenzimidazol-2-yl)piperidine (D5)
The title compound was prepared from isonipecotic acid and 2,3 diamino fluorobenzene using the method described in Description 4. MS m/e 220 (MH").
Description 6 4-(Benzoxazol-2-yl)piperidine (D6)
The title compound was prepared from isonipecotic acid and 2-aminophenol using the method described in Description 4. MS m e 203 (MH+).
Description 7 lH-Benzimidazol-2-yI piperazine (D7)
The title compound can be prepared according to procedures described in J. Med.
Chem., 1997, 40, 583-593.
Description 8 lH-Indol-3-yl piperidine (D8)
The title compound can be prepared according to procedures described in J. Med. Chem., 1992, 35(26), 4813.
Example 1
(R)-2-(l-(l-(Toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)-lH- benzimidazole (El) 2-(Piperidin-4-yl)-lH-benzimidazole (109 mg, 0.54 mmol) was added to a mixture of (R)-toluene-3-sulfonic acid 1 -(toluene-3 -sulfonyl)-pyrrolidin-2-yl methyl ester (Dl) (220 mg, 0.54 mmol), potassium carbonate (150 mg, 1.1 mmol) and sodium iodide (5mg) in acetonitile (10 mL) under argon. The reaction mixture was heated to reflux for 12 hours. Upon cooling, the solvent was removed in vacuo and the residue partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic phase was dried over sodium sulphate and concentrated in vacuo. Chromatography on silica gel afforded the title compound.
1Η NMR (CDC13) 7.65 (2Η, m), 7.41 (2H, m), 7.22 (4H, m), 3.76 (IH, m), 3.44 (IH, m), 3.15 - 2.91 (4H, m), 2.71 (IH, dd, 12.7, 3.9Hz), 2.44 (3H, s), 2.38 - 2.20 (4H, m), 2.17 - 1.75 (6H, m). MS m e 439 (MH+). Examples E2 - El 2 shown in Table 1 were prepared using the procedure described in Example 1 using either Dl or D2 and a 4-substituted piperidine or piperazine. Such reagents are either commercially available or can be prepared by methods described above.
Table 1
Examples El 3 - El 8 shown in Table 2 were prepared using the procedure described in Example 1 using D3 and a 4-substituted piperidine or piperazine. Such reagents are either commercially available or can be prepared by methods described above.
Table 2
Pharmacological Data H]-5-Carboxamidotryptamine binding to human 5-HT7 receptor clones expressed in 293 cells in vitro.
The affinity of the compounds of this invention for the 5-HT7 receptor binding site can be determined by methods described in WO 97/29097.
All compounds tested had a pKi in the range 6.0 - 7.9.

Claims

Claims:
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
(I) wherein: Rl, R2 and R^ are independently hydrogen, halogen, hydroxy, C\_ galkyl or C\_ galkoxy; m is 1 or 2;
X is nitrogen, carbon or a CH, is a single bond when X is nitrogen or CH; or is a double bond when X is carbon;
D is a single bond, C=O, O or CH2 subject to the proviso that when X is nitrogen then
D is not oxygen;
P is phenyl, naphthyl, a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
R4 is Ci .galkyl optionally substituted by NR^R6, aryl, arylCμg alkyl, C^ .galkoxy,
Ci.galkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR5R6, CONR5R6,
NR5COR6, S(O)pNR5R6, CHO, OCF3, SCF3, COR7, CH2OR7, CO2R7 or OR7 where p is 0, 1 or 2 and , R^ and R7 are independently hydrogen, Ci .galkyl, aryl or arylCi. galkyl; n is O, 1, 2 or 3.
2. A compound according to claim 1 in which R* is a methyl group with a meta relationship with respect to the sulphonamide linkage and both R^ and R^ are hydrogen.
3. A compound according to claim 1 or claim 2 in which D is a single bond.
4. A compound according to any one of the preceding claims in which P is benzimidazole.
5. A compound according to claim 1 which is (R)-2-(l-(l-(Toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)-lH- benzimidazole, (S)-2-( 1 -( 1 -(Toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzimidazole,
(RS)-2-(l-(l-(Toluene-3-sulfonyl)-piperidin-2-ylmethyl)-piperidin-4-yl)-lH- benzimidazole,
(R)-5-Fluoro-2-( 1 -(1 -(toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzimidazole,
(S)-5 -Fluoro-2-( 1 -( 1 -(toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzimidazole,
(RS)-5-Fluoro-2-(l-(l -(toluene-3 -sulfonyl)-piperidin-2-ylmethyl)-piperidin-4-yl)- 1H- benzimidazole, (R)-2-(l-(l -(Toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)-lH- benzoxazole,
(S)-2-( 1 -( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzoxazole,
(RS)-2-( 1 -( 1 -(Toluene-3 -sulfonyl)-piperidin-2-ylmethyl)-piperidin-4-yl)- 1 H- benzoxazole,
(R)-2-(4-( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2ylmethyl)-piperazin- 1 -yl)- 1 H- benzimidazole,
(S)-2-(4-( 1 -(Toluene-3 -sulfonyl)-pyrrolidin-2ylmethyl)-piperazin- 1 -yl)- 1 H- benzimidazole, (RS)-2-(4-(l -(Toluene-3-sulfonyl)-piperidin-2ylmethyl)-piperazin-l -yl)-lH- benzimidazole,
(R)- 1 -(2-Methoxy-phenyl)-4-( 1 -(toluene-3 -sulfonyl)-pyrrolidin-2-ylmethyl)- piperazine,
(S)-l-(2-Methoxy-phenyl)-4-(l -(toluene-3 -sulfonyl)-pyrrolidin-2-y lmethyl)- piperazine,
(RS)-l-(2-Methoxy-phenyl)-4-(l-(toluene-3-sulfonyl)-piperidin-2-ylmethyl)- piperazine,
(R)-3-(l -(1 -(Toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- lH-indole, (S)-3-( 1 -(1 -(Toluene-3-sulfonyl)-pyrrolidin-2-ylmethyl)-piperidin-4-yl)- 1 H-indole, (RS)-3-(l -( 1 -(Toluene-3 -sulfonyl)-piperidin-2-ylmethyl)-piperidin-4-yl)- 1 H-indole, or a pharmaceutically acceptable salt thereof.
6. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises coupling a compound of formula (II):
(II) in which Rl, R2, R3 and m are as defined in formula (I) and Y is a leaving group with a compound of formula (III)
(III) in which , X, D, P, n and R4 are as defined in formula (I); and optionally thereafter if appropriate: • removing any protecting groups;
• forming a pharmaceutically acceptable salt.
7. A compound according to any one of claims 1 to 5 for use in therapy.
8. A compound according to any one of claims 1 to 5 for use in the treatment of CNS disorders.
9. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier or excipient.
10. The use of a compound according to any one of claims 1 to 5 in the manufacture of a medicament for use in the treatment of depression and/or sleep disorders.
EP00935141A 1999-06-01 2000-05-25 Sulfonamide compounds with pharmaceutical activity Withdrawn EP1181287A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9912701.1A GB9912701D0 (en) 1999-06-01 1999-06-01 Novel compounds
GB9912701 1999-06-01
PCT/EP2000/004893 WO2000073299A1 (en) 1999-06-01 2000-05-25 Sulfonamide compounds with pharmaceutical activity

Publications (1)

Publication Number Publication Date
EP1181287A1 true EP1181287A1 (en) 2002-02-27

Family

ID=10854529

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00935141A Withdrawn EP1181287A1 (en) 1999-06-01 2000-05-25 Sulfonamide compounds with pharmaceutical activity

Country Status (5)

Country Link
EP (1) EP1181287A1 (en)
JP (1) JP2003500488A (en)
AU (1) AU5073400A (en)
GB (1) GB9912701D0 (en)
WO (1) WO2000073299A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
EP1541172A1 (en) * 2002-08-09 2005-06-15 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
WO2004069828A1 (en) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation Piperidine compound and medicinal use thereof
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
ES2319539T3 (en) 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv HETEROCICLICAL COMPOUNDS CONDENSED AS SEROTONINE RECEPTOR MODULATORS.
CN101213187B (en) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 Isoquinoline derivatives as inhibitors of RHO-kinase
CA2615577C (en) 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
BRPI0720986A2 (en) 2006-12-27 2014-03-11 Sanofi Aventis Substituted ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES
MX2009005964A (en) 2006-12-27 2009-06-15 Sanofi Aventis Cycloalkylamine substituted isoquinoline derivatives.
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
RU2468011C2 (en) 2006-12-27 2012-11-27 Санофи-Авентис Cycloalkylamine-substituted isoquinoline and isoquinolinone derivatives
MY148902A (en) 2006-12-27 2013-06-14 Sanofi Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
JP5421783B2 (en) 2006-12-27 2014-02-19 サノフイ Substituted isoquinolones and isoquinolinone derivatives as Rho kinase inhibitors
CA2728137C (en) 2008-06-24 2016-10-18 Sanofi-Aventis Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
MY153756A (en) 2008-06-24 2015-03-13 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
MY153615A (en) 2008-06-24 2015-02-27 Sanofi Aventis 6-substituted isoquinolines and isoquinolinones
JP5641436B2 (en) * 2011-03-28 2014-12-17 国立大学法人 鹿児島大学 Anti-HIV drugs
EA202092328A1 (en) 2018-05-11 2021-04-08 Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн NEW FUNCTIONALIZED LACTAMS AS MODULATORS OF 5-HYDROXYTRIPTAMIN RECEPTOR 7 AND METHOD OF THEIR APPLICATION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029097A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
WO1997049695A1 (en) * 1996-06-25 1997-12-31 Smithkline Beecham P.L.C. Sulfonamide derivatives as 5ht7 receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP1009405A4 (en) * 1997-08-28 2001-05-09 Merck & Co Inc MODULATORS OF PYRROLIDINE AND PIPERIDINE OF CHEMOKINE RECEPTOR ACTIVITY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029097A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
WO1997049695A1 (en) * 1996-06-25 1997-12-31 Smithkline Beecham P.L.C. Sulfonamide derivatives as 5ht7 receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0073299A1 *

Also Published As

Publication number Publication date
JP2003500488A (en) 2003-01-07
AU5073400A (en) 2000-12-18
GB9912701D0 (en) 1999-08-04
WO2000073299A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
WO2000073299A1 (en) Sulfonamide compounds with pharmaceutical activity
US6025367A (en) Sulfonamide derivatives as 5HT7 receptor antagonists
EP0912512B1 (en) Sulphonamide derivatives and their use in the treatment of cns disorders
US7439245B2 (en) Compounds
JP2004517072A (en) Compounds useful in treating CNS disorders
EP1392316B1 (en) Benzo[d]azepine derivatives as 5-ht6 receptor antagonists.
JP2005527463A (en) 3-Arylsulfonyl-7-piperazinyl-indole, -benzofuran and -benzothiophene with 5-HT6 receptor affinity for treating CNS diseases
WO2003066632A1 (en) Sulphonyl compounds with 5 -ht6 receptor affinity
SK280881B6 (en) 3-indolylpiperidine derivative, method of its preparation, its use for preparation of pharmaceutical composition and pharmaceutical composition
US6660751B1 (en) Sulfonamide derivatives as 5-HT7 receptor antagonists
US6849644B2 (en) Isoquinoline derivatives useful in the treatment of CNS disorders
JP2007504114A (en) 8- (1-Piperazinyl) quinoline derivatives and their use in the treatment of CNS diseases
RU2165420C2 (en) 1,2,5-thiadiazole derivatives of indolylalkyl-pyrimidinyl-piperazines and pharmaceutical composition based on these compounds
US6313145B1 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
RU2222535C2 (en) 3-tetrahydropyridine-4-ylindoles for treatment of psychotic disorders
US20030130275A1 (en) Sulfonamide compounds with pharmaceutical activity
WO1998052943A1 (en) Indoline derivatives as 5ht2c receptor antagonists
SK2192002A3 (en) Piperidine alcohol derivative, process for the preparation and use thereof and pharmaceutical composition comprising same
JPS6197283A (en) Piperidine derivative, manufacture and medicinal composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020408

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021219